Celcuity Inc.
CELCHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Celcuity Inc. focuses on Biotechnology services and products. Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The $6.48B market capitalization puts CELC squarely in mid-cap range for its industry. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Market Cap
$6.48B
Beta
0.09
P/E (TTM)
—
P/E (Fwd)
179.57
EPS (TTM)
$-3.90
EPS (Fwd)
$0.74
ROE
-275.2%
ROA
-37.1%
Cash
$387.1M
Total Debt
$323.4M
Free CF
-$110.8M
52W Change
1043.5%
Annual Financials
Cash vs Debt
With $387.1M in cash and $323.4M in debt, CELC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$110.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -275.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
CELC's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Celcuity Inc.'s trajectory.